[Role of FDG-PET in oncological surgery].
Fluorine-18 fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) allows in vivo analysis of tissue metabolic activity. Based on the observation that most malignant tumors display a higher metabolic activity than benign tissues, [18F]FDG-PET offers an interesting option for the diagnosis of primary and recurrent malignant tumors. For the oncological surgeon [18F]FDG-PET is particularly helpful for the diagnosis of tumors of the pancreas, colorectum, lung and esophagus. This short review describes the biological basis of [18F]FDG-PET and gives a critical discussion of its role in oncological surgery.
Schürmann
G
G
Klinik und Poliklinik für Allgemeine Chirurgie, Westfälische Wilhelms-Universität Münster. gschurm@uni-muenster.de
Franzius
C
C
Twelker
L
L
Senninger
N
N
Schober
O
O
D001786:Blood Glucose / Q000378:metabolism*; D004734:Energy Metabolism / Q000502:physiology; D019788:Fluorodeoxyglucose F18; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000601:surgery; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000503:physiopathology / Q000601:surgery; D011237:Predictive Value of Tests; D012086:Reoperation; D014055:Tomography, Emission-Computed
D001786:Blood Glucose; D019788:Fluorodeoxyglucose F18